ReviewCells2020
Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Immune aging and infectious diseases.Chinese medical journal · 2024Review
- The Impact of Immune System Aging on Infectious Diseases.Microorganisms · 2024Review
- Cdc42 improve SARS-CoV-2 spike protein-induced cellular senescence through activating of Wnt/β-Catenin signaling pathway.Frontiers in cellular and infection microbiology · 2024Article
- Mitochondria in COVID-19: from cellular and molecular perspective.Frontiers in physiology · 2024Review
- Review
- Article
- Treatment with the senolytics dasatinib/quercetin reduces SARS-CoV-2-related mortality in mice.Aging cell · 2023Article
- Global Research Trends and Hotspots on Mitochondria in Acute Lung Injury from 2012-2021: A Bibliometric Analysis.International journal of environmental research and public health · 2022Article
- Article
- SARS-CoV-2 modulation of RIG-I-MAVS signaling: Potential mechanisms of impairment on host antiviral immunity and therapeutic approaches.MedComm - future medicine · 2022Article
- A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions.Phytotherapy research : PTR · 2022Review
- Understanding the role of telomere attrition and epigenetic signatures in COVID-19 severity.Gene · 2022Review
- Does COVID-19 Escalate Aging Process? A Possible Concern.Advanced biomedical research · 2022Article
- COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis.Research square · 2021Article
- The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditions.Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2021Review
- Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly.Inflammopharmacology · 2021Review
- COVID-19, ferrosenescence and neurodegeneration, a mini-review.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- SARS-CoV-2 Neuronal Invasion and Complications: Potential Mechanisms and Therapeutic Approaches.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Review
- Glycyrrhizin mitigates inflammatory bone loss and promotes expression of senescence-protective sirtuins in an aging mouse model of periprosthetic osteolysis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting.Transplant infectious disease : an official journal of the Transplantation Society · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The higher death rate caused by COVID-19 in older people, especially those with comorbidities, is a challenge for biomedical aging research. Here we explore the idea that an exacerbated inflammatory response, in particular that mediated by IL-6, may drive the deleterious consequences of the infection. Data shows that other RNA viruses, such as influenza virus, can display enhanced replication efficiency in senescent cells, suggesting that the accumulation of senescent cells with aging and age-related diseases may play a role in this phenomenon. However, at present, we are completely unaware of the response to SARS-CoV and SARS-COV-2 occurring in senescent cells. We deem that this is a priority area of research because it could lead to the development of several therapeutic strategies based on senotherapeutics or prevent unsuccessful attempts. Two of these senotherapeutics, azithromycin and ruxolitinib, are currently undergoing testing for their efficacy in treating COVID-19. The potential of these strategies is not only for ameliorating the consequences of the current emergence of SARS-CoV-2, but also for the future emergence of new viruses or mutated ones for which we are completely unprepared and for which no vaccines are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.